CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE4

Enrollment: 45

Sponsor: Fernanda P Silveira, MD, MS

Summary

Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients. CytoGam - Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV), is an immunoglobulin G containing a standardized amount of antibody against CMV. CytoGam is obtained from pooled adult human plasma that has been selected for high anti-CMV titers. This study will evaluate if administration of CytoGam to organ transplant recipients with CMV infection, along with standard of care antiviral medication, leads to faster clearance of CMV from the blood, prevents the development of antiviral resistance, and decreases the rate of recurrence of CMV infection.

Eligibility Criteria

Inclusion Criteria - all study arms: * Written informed consent obtained from the subject before any trial-related procedures are performed * \>= 18 years and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07009548). StuddyBuddy aggregates publicly available trial information.